The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Nature64.80
Volume: 537, Issue: 7618, Pages: 50 - 56
Published: Sep 1, 2016
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model...
Paper Details
Title
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Published Date
Sep 1, 2016
Journal
Volume
537
Issue
7618
Pages
50 - 56
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.